grant
Molecular pathogenesis of COVID-19-associated coagulopathy and new therapeutic approaches
Organization SCRIPPS RESEARCH INSTITUTE, THELocation LA JOLLA, UNITED STATESPosted 1 Jan 2024Deadline 31 Dec 2028
NIHUS FederalResearch GrantFY20262019 novel corona virus2019 novel coronavirus2019-nCoVACE2AddressAndrogenic AgentsAndrogenic CompoundsAndrogensAutomobile DrivingBasic ResearchBasic ScienceBiologyBlood Coagulation DisordersBlood NeutrophilBlood PlateletsBlood Polymorphonuclear NeutrophilBlood monocyteCOVID crisisCOVID disease severityCOVID epidemicCOVID infected patientCOVID pandemicCOVID patientCOVID positive patientCOVID severityCOVID-19COVID-19 affectedCOVID-19 consequenceCOVID-19 crisisCOVID-19 disease severityCOVID-19 effectCOVID-19 epidemicCOVID-19 eraCOVID-19 global health crisisCOVID-19 global pandemicCOVID-19 health crisisCOVID-19 impactCOVID-19 impactedCOVID-19 infected patientCOVID-19 infectionCOVID-19 pandemicCOVID-19 pathogenesisCOVID-19 patientCOVID-19 periodCOVID-19 positive patientCOVID-19 predispositionCOVID-19 preventionCOVID-19 public health crisisCOVID-19 severityCOVID-19 susceptibilityCOVID-19 therapyCOVID-19 treatmentCOVID-19 virusCOVID-19 virus infectionCOVID-19 vulnerabilityCOVID-19 yearsCOVID19 disease severityCOVID19 infectionCOVID19 pathogenesisCOVID19 patientCOVID19 positive patientCOVID19 severityCOVID19 virusCV-19Cell BodyCellsChinaClinicalClottingCoV-2CoV2CoagulationCoagulation DisorderCoagulation ProcessCoagulopathyComplexCoronavirus Infectious Disease 2019Coronavirus disease 2019 predispositionCoronavirus disease 2019 susceptibilityCoronavirus disease 2019 vulnerabilityDataDeep Vein ThrombosisDeep-Venous ThrombosisDevelopmentDifferences between sexesDiffers between sexesDiseaseDisease ProgressionDisorderDysfunctionEndocrine Gland SecretionEndotheliumEstrogensFemaleFibrinFunctional disorderGender BiasGoalsHemostasisHemostatic AgentsHemostatic functionHemostaticsHormonalHormonesHost Defense MechanismHumanHypercoagulabilityImmuneImmune Cell ActivationImmune TargetingImmune responseImmunesIncidenceInfectionInflammatory ResponseIntervention StudiesInvestigatorsK-18K-18 conjugateK18K18 combinationKnowledgeLinkLong COVIDLong COVID-19Long coronavirus diseaseLong coronavirus disease 2019Mainland ChinaMarrow NeutrophilMarrow monocyteMarrow plateletMediatingMiceMice MammalsModelingModern ManMolecularMurineMusNamesNeutrophil ActivationNeutrophilic GranulocyteNeutrophilic LeukocyteOrganOutcomePathologicPathway interactionsPatientsPhysiopathologyPlateletsPlayPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPredisposed to COVID-19Predisposed to SARS-CoV-2Predisposed to Severe acute respiratory syndrome coronavirus 2PredispositionProteinsPulmonary EmbolismRecoveryReportingResearchResearch PersonnelResearchersRespiratory DiseaseRespiratory System DiseaseRespiratory System DisorderRiskRistocetin CofactorRistocetin-Willebrand FactorRoleSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 disease severitySARS-CoV-2 epidemicSARS-CoV-2 global health crisisSARS-CoV-2 global pandemicSARS-CoV-2 infected patientSARS-CoV-2 infectionSARS-CoV-2 pandemicSARS-CoV-2 patientSARS-CoV-2 positive patientSARS-CoV-2 predispositionSARS-CoV-2 severitySARS-CoV-2 susceptibilitySARS-CoV-2 therapySARS-CoV-2 treatmentSARS-CoV-2 vulnerabilitySARS-CoV2SARS-CoV2 infectionSARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-coronavirus-2 epidemicSARS-coronavirus-2 pandemicSARS-related corona virus 2SARS-related coronavirus 2SARSCoV2Severe Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome CoV 2 epidemicSevere Acute Respiratory Syndrome CoV 2 pandemicSevere Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome coronavirus 2 epidemicSevere acute respiratory syndrome coronavirus 2 infectionSevere acute respiratory syndrome coronavirus 2 pandemicSevere acute respiratory syndrome coronavirus 2 predispositionSevere acute respiratory syndrome coronavirus 2 susceptibilitySevere acute respiratory syndrome coronavirus 2 vulnerabilitySevere acute respiratory syndrome related corona virus 2SeveritiesSeverity of illnessSex BiasSex DifferencesSexual DevelopmentSexual differencesSpecificitySupplementationSusceptibilitySyndromeSystemTherapeuticTherapeutic AndrogenTherapeutic EffectTherapeutic EstrogenTherapeutic InterventionThrombocytesThrombophiliaThrombosisThrombusTimeTranslational ResearchTranslational ScienceVascular DiseasesVascular DisorderViral DiseasesVirusVirus DiseasesWuhan coronavirusafter COVID-19 infectionafter SARS-CoV-2 infectionafter SARS-CoV2 infectionafter infection by SARS-CoV-2after severe acute respiratory distress syndrome CoV-2 infectionangiotensin converting enzyme 2angiotensin converting enzyme IIbleeding disorderblood vessel disorderchronic COVIDchronic COVID-19chronic novel coronavirus disease 2019clotting disordercombatcomplement pathwaycoronavirus disease 2019coronavirus disease 2019 consequencecoronavirus disease 2019 crisiscoronavirus disease 2019 disease severitycoronavirus disease 2019 effectcoronavirus disease 2019 epidemiccoronavirus disease 2019 global health crisiscoronavirus disease 2019 global pandemiccoronavirus disease 2019 health crisiscoronavirus disease 2019 impactcoronavirus disease 2019 infected patientcoronavirus disease 2019 infectioncoronavirus disease 2019 pandemiccoronavirus disease 2019 pathogenesiscoronavirus disease 2019 patientcoronavirus disease 2019 positive patientcoronavirus disease 2019 preventioncoronavirus disease 2019 public health crisiscoronavirus disease 2019 severitycoronavirus disease 2019 therapycoronavirus disease 2019 treatmentcoronavirus disease 2019 viruscoronavirus disease crisiscoronavirus disease epidemiccoronavirus disease infected patientcoronavirus disease pandemiccoronavirus disease patientcoronavirus disease positive patientcoronavirus disease severitycoronavirus disease-19coronavirus disease-19 global pandemiccoronavirus disease-19 impactcoronavirus disease-19 pandemiccoronavirus disease-19 pathogenesiscoronavirus disease-19 patientcoronavirus disease-19 preventioncoronavirus disease-19 viruscoronavirus infectious disease-19coronavirus patientdesigndesigningdevelopmentaldisease severitydrivingefficacy testingexperiences among menextracellularfeasibility testingfollowing COVID-19 infectionfollowing SARS-CoV-2 infectionfollowing SARS-CoV2 infectionfollowing infection by SARS-CoV-2following severe acute respiratory distress syndrome CoV-2 infectionhCoV19host responseimmune activationimmune cell-mediated thrombosisimmune system responseimmune-mediated thrombosisimmunoresponseimmunothrombosisimmunothromboticin vivoinfected with COVID-19infected with COVID19infected with SARS-CoV-2infected with SARS-CoV2infected with coronavirus disease 2019infected with severe acute respiratory syndrome coronavirus 2infection with SARS-CoV-2insightintervention researchintervention therapyinterventional researchinterventional studyinterventions researchlife-threatening COVIDlife-threatening COVID-19life-threatening SARS-CoV-2life-threatening coronavirus diseaselife-threatening coronavirus disease 2019life-threatening severe acute respiratory syndrome coronavirus 2long haul COVIDlong haul COVID-19long haul coronavirus diseaselong haul coronavirus disease 2019long-hauler COVIDlong-hauler COVID-19long-hauler coronavirus disease 2019long-hauler syndromelong-term COVIDlong-term COVID-19long-term coronavirus diseaselong-term coronavirus disease 2019malemale experiencemen's experiencemolecular targeted therapeuticsmolecular targeted therapiesmolecular targeted treatmentmonocytemortalitymouse modelmurine modelnCoV2namenamednamingneutrophilnew approachesnew drug targetnew drug treatmentsnew druggable targetnew drugsnew pharmacological therapeuticnew pharmacotherapy targetnew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapeutic targetnew therapeuticsnew therapynew therapy approachesnew therapy targetnew treatment approachnew treatment strategynext generation therapeuticsnovelnovel approachesnovel drug targetnovel drug treatmentsnovel druggable targetnovel drugsnovel pharmaco-therapeuticnovel pharmacological therapeuticnovel pharmacotherapy targetnovel strategiesnovel strategynovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapeutic targetnovel therapeuticsnovel therapynovel therapy approachnovel therapy targetpandemicpandemic diseasepathogenpathogenic viruspathophysiologypathwaypatient infected with COVIDpatient infected with COVID-19patient infected with SARS-CoV-2patient infected with coronavirus diseasepatient infected with coronavirus disease 2019patient infected with severe acute respiratory syndrome coronavirus 2patient with COVIDpatient with COVID-19patient with COVID19patient with SARS-CoV-2patient with coronavirus diseasepatient with coronavirus disease 2019patient with severe acute respiratory distress syndrome coronavirus 2persistent COVID-19pharmacologicplatelet functionpost COVID syndromepost COVID-19 syndromepost SARS-CoV-2 infectionpost acute COVID syndromepost acute COVID-19post acute COVID-19 syndromepost acute SARS-CoV-2post acute coronavirus disease 2019post acute coronavirus disease 2019 syndromepost acute coronavirus disease syndromepost acute severe acute respiratory syndrome coronavirus 2post coronavirus disease 2019 syndromepost coronavirus disease syndromepost-acute phases of COVID-19predisposed to Coronavirus disease 2019prevent COVID-19prevent coronavirus disease 2019previous COVID-19 infectionprevious SARS-CoV-2 infectionprevious SARS-CoV2 infectionprevious severe acute respiratory distress syndrome CoV-2 infectionprior COVID-19 infectionprior SARS-CoV-2 infectionprior SARS-CoV2 infectionprior severe acute respiratory distress syndrome CoV-2 infectionprolonged COVID-19 symptomsrecruitresponseserious COVIDserious COVID-19serious SARS-CoV-2serious coronavirus diseaseserious coronavirus disease 2019serious severe acute respiratory syndrome coronavirus 2severe COVIDsevere COVID-19severe COVID19severe SARS-CoV-2severe acute respiratory syndrome coronavirus 2 disease severitysevere acute respiratory syndrome coronavirus 2 global health crisissevere acute respiratory syndrome coronavirus 2 global pandemicsevere acute respiratory syndrome coronavirus 2 infected patientsevere acute respiratory syndrome coronavirus 2 patientsevere acute respiratory syndrome coronavirus 2 positive patientsevere acute respiratory syndrome coronavirus 2 severitysevere acute respiratory syndrome coronavirus 2 therapysevere acute respiratory syndrome coronavirus 2 treatmentsevere coronavirus diseasesevere coronavirus disease 19severe coronavirus disease 2019severe severe acute respiratory syndrome coronavirus 2sexsex based differencessex developmentsex-dependent differencessex-related differencessex-specific differencessocial rolesuccesssusceptible to COVID-19susceptible to Coronavirus disease 2019susceptible to SARS-CoV-2susceptible to Severe acute respiratory syndrome coronavirus 2targeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmentthromboinflammationthromboinflammatorythrombotic diseasethrombotic disordertranslation researchtranslational investigationtreat COVID-19treat SARS-CoV-2treat coronavirus disease 2019treat severe acute respiratory syndrome coronavirus 2vascular dysfunctionvasculopathyvenous thromboembolismviral infectionviral pathogenvirus infectionvirus pathogenvirus-induced diseasevon Willebrand Factorvon Willebrand Proteinvulnerable to COVID-19vulnerable to Coronavirus disease 2019vulnerable to SARS-CoV-2vulnerable to Severe acute respiratory syndrome coronavirus 2♀♂
Description preview
Project Summary
Many studies have highlighted a large incidence of hemostatic derangements in the form of hypercoagulable
and hypofibrinolytic states following SARS-CoV-2 infection. These hemostatic disturbances are fueled by and a
consequence of the concomitant activation of the endothelium following a severe inflammatory response, with
likely…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click